News Archives | disease models

We are happy to announce that we have established MD Biosciences Neuro, LLC. in Cambridge, Massachusetts to expand our work and collaborations in the United States. Our team, led by Chief Scientific Officer, Sigal Meilin, is looking forward to developing close partnerships with you and continuing to advance the field of neurology and pain research.
With a multifaceted approach to assessment of neurological diseases, specializations include pain-related work, neurodegenerative diseases including Parkinson's, neuro-inflammatory diseases such as Multiple Sclerosis (MS), and capabilities in stroke and cerebral ischemia. Preclinical models are complimented by in house histology, biomarker analysis and electrophysiology capabilities. Finally, our unique porcine models share a high degree of similarity to humans, thus offering greater clinical efficacy that serve to augment and accelerate your program towards their next objectives and milestones.

Please contact us with any questions about our services, capabilities, and customizable study design options.

Due to the clinical and pathological similarities of experimental autoimmune encephalomyelitis (EAE) and Multiple Sclerosis (MS), EAE is a model for the study of human demyelinating disease. Both EAE and MS are characterized by a relapsing-remitting disease course with subsequent progressive disability. EAE is characterized by chronic inflammatory demyelination of the central nervous system (CNS) and involves autoimmune CD4+ Th1 cells. These cells develop in the peripheral lymphoid organ and travel to the CNS causing an immune response. The development of T cells is controlled largely by the expression of various cytokines, as well as cellular adhesion molecules.

This past month in Paris, our scientists presented at the NeuroImmunology Conference, where they shared novel data in the Myelin Basic Protein (MBP) Induced model used to mimic Multiple Sclerosis (MS). This model is a powerful tool for studying disease pathogenesis as well as potential therapeutic interventions. Below find our poster data.

When conducting MS research, administration of one dose of MPB in a Lewis rat leads to a single relapse that is characterized by hind paw paralysis. This can be characterized histologically, by infiltration of mononuclear cells to the cervical spinal cord and formation of foci. This model is self-limiting and does not show demyelination.